 Lisa Schilling
Concepts (336)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 12 | 2024 | 977 | 1.340 |
Why?
| | Periodicals as Topic | 11 | 2008 | 204 | 1.300 |
Why?
| | Decision Support Systems, Clinical | 2 | 2022 | 206 | 1.220 |
Why?
| | Comparative Effectiveness Research | 4 | 2017 | 147 | 0.970 |
Why?
| | Patient-Centered Care | 2 | 2024 | 501 | 0.960 |
Why?
| | Quality Improvement | 6 | 2024 | 1103 | 0.950 |
Why?
| | Data Mining | 2 | 2017 | 110 | 0.880 |
Why?
| | Medical Informatics | 5 | 2024 | 99 | 0.870 |
Why?
| | Information Storage and Retrieval | 7 | 2021 | 107 | 0.840 |
Why?
| | Maternal Health Services | 1 | 2024 | 92 | 0.790 |
Why?
| | Publishing | 7 | 2007 | 140 | 0.790 |
Why?
| | Ultraviolet Rays | 6 | 2015 | 383 | 0.770 |
Why?
| | Urinary Tract Infections | 1 | 2023 | 151 | 0.750 |
Why?
| | Critical Pathways | 1 | 2022 | 86 | 0.730 |
Why?
| | Dermatology | 8 | 2021 | 117 | 0.670 |
Why?
| | Internet | 10 | 2018 | 620 | 0.620 |
Why?
| | Sunbathing | 2 | 2015 | 14 | 0.610 |
Why?
| | Skin Neoplasms | 7 | 2015 | 830 | 0.600 |
Why?
| | Hypertension | 5 | 2022 | 1235 | 0.600 |
Why?
| | Blood Pressure Determination | 1 | 2018 | 148 | 0.550 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2022 | 429 | 0.510 |
Why?
| | Evidence-Based Medicine | 4 | 2024 | 715 | 0.500 |
Why?
| | Medical Record Linkage | 4 | 2024 | 61 | 0.490 |
Why?
| | Biomedical Research | 5 | 2021 | 639 | 0.490 |
Why?
| | Safety-net Providers | 2 | 2019 | 110 | 0.480 |
Why?
| | Primary Health Care | 7 | 2023 | 1677 | 0.480 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 126 | 0.460 |
Why?
| | Leadership | 2 | 2024 | 358 | 0.450 |
Why?
| | Attitude of Health Personnel | 4 | 2016 | 1102 | 0.450 |
Why?
| | Foot Deformities, Congenital | 1 | 2013 | 1 | 0.440 |
Why?
| | Health Maintenance Organizations | 2 | 2011 | 97 | 0.440 |
Why?
| | Melanoma | 4 | 2021 | 728 | 0.430 |
Why?
| | Myotonic Dystrophy | 1 | 2013 | 8 | 0.430 |
Why?
| | Contracture | 1 | 2013 | 21 | 0.430 |
Why?
| | Spinal Diseases | 1 | 2013 | 47 | 0.420 |
Why?
| | Quality Indicators, Health Care | 3 | 2010 | 297 | 0.420 |
Why?
| | Benchmarking | 2 | 2011 | 175 | 0.420 |
Why?
| | Surveys and Questionnaires | 12 | 2022 | 5429 | 0.410 |
Why?
| | Humans | 75 | 2025 | 129527 | 0.410 |
Why?
| | Algorithms | 5 | 2025 | 1614 | 0.410 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2018 | 250 | 0.400 |
Why?
| | Databases, Factual | 6 | 2024 | 1261 | 0.400 |
Why?
| | Peer Review, Research | 3 | 2007 | 41 | 0.390 |
Why?
| | Beauty Culture | 4 | 2005 | 12 | 0.380 |
Why?
| | United States | 27 | 2024 | 13865 | 0.370 |
Why?
| | Medication Adherence | 1 | 2016 | 560 | 0.350 |
Why?
| | Total Quality Management | 1 | 2010 | 60 | 0.350 |
Why?
| | Internal Medicine | 5 | 2006 | 245 | 0.340 |
Why?
| | Databases, Bibliographic | 3 | 2004 | 30 | 0.340 |
Why?
| | Information Management | 2 | 2012 | 17 | 0.330 |
Why?
| | Transgender Persons | 2 | 2023 | 172 | 0.320 |
Why?
| | Models, Statistical | 1 | 2012 | 624 | 0.290 |
Why?
| | Information Dissemination | 1 | 2010 | 204 | 0.290 |
Why?
| | Fractures, Bone | 1 | 2013 | 395 | 0.290 |
Why?
| | Tretinoin | 1 | 2009 | 121 | 0.290 |
Why?
| | Internship and Residency | 4 | 2006 | 1049 | 0.280 |
Why?
| | Adult | 21 | 2024 | 35505 | 0.260 |
Why?
| | Cause of Death | 1 | 2009 | 395 | 0.260 |
Why?
| | Anticholesteremic Agents | 2 | 2005 | 146 | 0.260 |
Why?
| | Middle Aged | 23 | 2024 | 31087 | 0.260 |
Why?
| | Access to Information | 1 | 2006 | 47 | 0.250 |
Why?
| | Clofibric Acid | 1 | 2005 | 1 | 0.250 |
Why?
| | Disclosure | 1 | 2007 | 110 | 0.250 |
Why?
| | Aged | 19 | 2024 | 22063 | 0.250 |
Why?
| | Adolescent | 20 | 2024 | 20409 | 0.250 |
Why?
| | Female | 31 | 2024 | 68650 | 0.250 |
Why?
| | Physician-Patient Relations | 5 | 2002 | 539 | 0.250 |
Why?
| | Office Visits | 2 | 2002 | 86 | 0.240 |
Why?
| | Archives | 1 | 2004 | 4 | 0.230 |
Why?
| | Libraries, Digital | 1 | 2004 | 4 | 0.230 |
Why?
| | Comorbidity | 7 | 2022 | 1548 | 0.230 |
Why?
| | Observational Studies as Topic | 1 | 2025 | 110 | 0.230 |
Why?
| | Health Information Interoperability | 1 | 2024 | 3 | 0.230 |
Why?
| | Spain | 5 | 2021 | 33 | 0.230 |
Why?
| | Biological Products | 2 | 2024 | 207 | 0.230 |
Why?
| | Gemfibrozil | 2 | 2006 | 11 | 0.230 |
Why?
| | Platelet Transfusion | 1 | 2024 | 61 | 0.220 |
Why?
| | Lovastatin | 2 | 2006 | 37 | 0.220 |
Why?
| | Legislation as Topic | 1 | 2003 | 3 | 0.210 |
Why?
| | Hospitalization | 6 | 2022 | 2076 | 0.210 |
Why?
| | Osteoporotic Fractures | 1 | 2023 | 57 | 0.200 |
Why?
| | Young Adult | 10 | 2023 | 12438 | 0.200 |
Why?
| | Programming Languages | 2 | 2021 | 23 | 0.200 |
Why?
| | Anticarcinogenic Agents | 1 | 2003 | 77 | 0.200 |
Why?
| | Erythrocyte Transfusion | 1 | 2024 | 182 | 0.190 |
Why?
| | Patient Acceptance of Health Care | 3 | 2023 | 761 | 0.190 |
Why?
| | Male | 28 | 2024 | 63586 | 0.190 |
Why?
| | Pregnancy Outcome | 1 | 2024 | 391 | 0.180 |
Why?
| | Computer Communication Networks | 1 | 2021 | 32 | 0.180 |
Why?
| | Depressive Disorder, Major | 1 | 2025 | 344 | 0.180 |
Why?
| | Drug Repositioning | 1 | 2021 | 26 | 0.180 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 278 | 0.180 |
Why?
| | Confidentiality | 1 | 2021 | 68 | 0.180 |
Why?
| | Perception | 1 | 2023 | 346 | 0.180 |
Why?
| | Quality of Health Care | 3 | 2024 | 607 | 0.170 |
Why?
| | Osteoporosis | 1 | 2023 | 231 | 0.170 |
Why?
| | Aged, 80 and over | 8 | 2023 | 7052 | 0.170 |
Why?
| | Influenza, Human | 3 | 2021 | 602 | 0.170 |
Why?
| | Cohort Studies | 8 | 2023 | 5423 | 0.170 |
Why?
| | Natural Language Processing | 1 | 2021 | 94 | 0.170 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 2044 | 0.160 |
Why?
| | Computational Biology | 1 | 2004 | 591 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2021 | 376 | 0.160 |
Why?
| | Faculty, Medical | 1 | 2003 | 268 | 0.160 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 196 | 0.160 |
Why?
| | Pandemics | 4 | 2021 | 1500 | 0.160 |
Why?
| | Alzheimer Disease | 1 | 2025 | 516 | 0.160 |
Why?
| | Database Management Systems | 2 | 2012 | 48 | 0.160 |
Why?
| | Pregnancy Complications | 1 | 2024 | 493 | 0.160 |
Why?
| | Patient Care Team | 1 | 2024 | 600 | 0.150 |
Why?
| | Student Health Services | 1 | 2018 | 15 | 0.150 |
Why?
| | Language | 1 | 2021 | 283 | 0.150 |
Why?
| | Occupational Health | 1 | 2021 | 193 | 0.150 |
Why?
| | Hypersensitivity | 1 | 2021 | 249 | 0.150 |
Why?
| | Patient Portals | 1 | 2018 | 42 | 0.140 |
Why?
| | Artificial Intelligence | 1 | 2021 | 245 | 0.140 |
Why?
| | Health Plan Implementation | 1 | 2019 | 136 | 0.140 |
Why?
| | Communication | 2 | 2020 | 843 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2009 | 1368 | 0.140 |
Why?
| | Republic of Korea | 3 | 2021 | 29 | 0.140 |
Why?
| | Asthma | 2 | 2022 | 2225 | 0.130 |
Why?
| | Phenotype | 1 | 2025 | 3058 | 0.130 |
Why?
| | Authorship | 2 | 2007 | 46 | 0.130 |
Why?
| | Health Care Surveys | 3 | 2016 | 557 | 0.130 |
Why?
| | Curriculum | 3 | 2024 | 922 | 0.130 |
Why?
| | Palliative Care | 1 | 2022 | 704 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 342 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 336 | 0.120 |
Why?
| | Advance Care Planning | 1 | 2018 | 201 | 0.120 |
Why?
| | Academic Medical Centers | 4 | 2023 | 478 | 0.120 |
Why?
| | Education, Medical | 2 | 2011 | 252 | 0.120 |
Why?
| | Review Literature as Topic | 2 | 2006 | 66 | 0.120 |
Why?
| | Hyperlipidemias | 1 | 2016 | 118 | 0.120 |
Why?
| | Health Personnel | 1 | 2021 | 654 | 0.120 |
Why?
| | Health Education | 1 | 2018 | 334 | 0.120 |
Why?
| | Practice Patterns, Physicians' | 2 | 2016 | 1257 | 0.110 |
Why?
| | Trichotillomania | 1 | 2014 | 6 | 0.110 |
Why?
| | Prevalence | 4 | 2021 | 2561 | 0.110 |
Why?
| | Decision Support Techniques | 1 | 2018 | 401 | 0.110 |
Why?
| | Patient Satisfaction | 4 | 2002 | 636 | 0.110 |
Why?
| | Models, Theoretical | 1 | 2017 | 548 | 0.110 |
Why?
| | Affective Symptoms | 1 | 2014 | 51 | 0.110 |
Why?
| | Early Detection of Cancer | 1 | 2018 | 371 | 0.110 |
Why?
| | Hypertension, Pulmonary | 1 | 2025 | 1891 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 988 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1708 | 0.110 |
Why?
| | Retrospective Studies | 4 | 2021 | 14532 | 0.100 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 1918 | 0.100 |
Why?
| | France | 2 | 2021 | 29 | 0.100 |
Why?
| | Referral and Consultation | 3 | 2023 | 732 | 0.100 |
Why?
| | Ambulatory Care | 3 | 2006 | 507 | 0.090 |
Why?
| | Obesity | 2 | 2022 | 2875 | 0.090 |
Why?
| | Pregnancy | 1 | 2024 | 6412 | 0.090 |
Why?
| | Medical Records Systems, Computerized | 1 | 2012 | 93 | 0.090 |
Why?
| | Thalassemia | 1 | 2011 | 6 | 0.090 |
Why?
| | Quality Assurance, Health Care | 2 | 2010 | 316 | 0.090 |
Why?
| | Planning Techniques | 1 | 2010 | 16 | 0.090 |
Why?
| | Health Services Research | 2 | 2012 | 389 | 0.090 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 744 | 0.090 |
Why?
| | Organizational Objectives | 1 | 2010 | 72 | 0.090 |
Why?
| | Child, Preschool | 4 | 2021 | 10499 | 0.090 |
Why?
| | Disaster Planning | 1 | 2011 | 83 | 0.090 |
Why?
| | Cost Savings | 1 | 2010 | 78 | 0.090 |
Why?
| | Child | 7 | 2021 | 20932 | 0.080 |
Why?
| | Heart Diseases | 1 | 2013 | 349 | 0.080 |
Why?
| | Health Records, Personal | 1 | 2010 | 26 | 0.080 |
Why?
| | Safety Management | 1 | 2010 | 112 | 0.080 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 133 | 0.080 |
Why?
| | Organizational Innovation | 1 | 2010 | 137 | 0.080 |
Why?
| | Organizational Culture | 1 | 2010 | 139 | 0.080 |
Why?
| | Emotions | 1 | 2014 | 545 | 0.080 |
Why?
| | Infant | 3 | 2021 | 9005 | 0.080 |
Why?
| | Administration, Topical | 1 | 2009 | 147 | 0.070 |
Why?
| | Codes of Ethics | 1 | 2008 | 17 | 0.070 |
Why?
| | Human Experimentation | 1 | 2008 | 12 | 0.070 |
Why?
| | Colorado | 6 | 2024 | 4403 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2010 | 276 | 0.070 |
Why?
| | Age Factors | 3 | 2020 | 3150 | 0.070 |
Why?
| | Self-Evaluation Programs | 1 | 2007 | 6 | 0.070 |
Why?
| | Lung Diseases | 1 | 2013 | 741 | 0.070 |
Why?
| | Scientific Misconduct | 1 | 2007 | 12 | 0.070 |
Why?
| | Ethics, Research | 1 | 2007 | 31 | 0.070 |
Why?
| | Public Health | 1 | 2011 | 484 | 0.070 |
Why?
| | Neoplasms | 1 | 2021 | 2450 | 0.070 |
Why?
| | Bibliometrics | 1 | 2007 | 53 | 0.070 |
Why?
| | Students, Medical | 2 | 2011 | 323 | 0.060 |
Why?
| | Smallpox Vaccine | 1 | 2006 | 23 | 0.060 |
Why?
| | Hypolipidemic Agents | 1 | 2006 | 88 | 0.060 |
Why?
| | Knowledge | 1 | 2006 | 50 | 0.060 |
Why?
| | Family Practice | 1 | 2010 | 456 | 0.060 |
Why?
| | Medical Staff, Hospital | 1 | 2006 | 81 | 0.060 |
Why?
| | Clinical Clerkship | 1 | 2007 | 96 | 0.060 |
Why?
| | Vaccination | 2 | 2021 | 1348 | 0.060 |
Why?
| | Research Design | 2 | 2014 | 1043 | 0.060 |
Why?
| | Indiana | 1 | 2024 | 33 | 0.060 |
Why?
| | Health Level Seven | 1 | 2024 | 2 | 0.060 |
Why?
| | Vocabulary, Controlled | 1 | 2024 | 45 | 0.060 |
Why?
| | Data Accuracy | 1 | 2024 | 58 | 0.060 |
Why?
| | Editorial Policies | 1 | 2004 | 48 | 0.050 |
Why?
| | Blood Banks | 1 | 2024 | 40 | 0.050 |
Why?
| | Teaching | 1 | 2006 | 217 | 0.050 |
Why?
| | Taxes | 1 | 2003 | 11 | 0.050 |
Why?
| | Risk Factors | 3 | 2021 | 9779 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2018 | 1283 | 0.050 |
Why?
| | Managed Care Programs | 2 | 2002 | 128 | 0.050 |
Why?
| | Medical Staff | 1 | 2002 | 16 | 0.050 |
Why?
| | Absorptiometry, Photon | 1 | 2023 | 246 | 0.050 |
Why?
| | Testosterone Congeners | 1 | 2022 | 8 | 0.050 |
Why?
| | Chemoprevention | 1 | 2003 | 91 | 0.050 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5078 | 0.050 |
Why?
| | Documentation | 1 | 2004 | 184 | 0.050 |
Why?
| | Intensive Care Units | 1 | 2007 | 737 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2003 | 170 | 0.050 |
Why?
| | Gender Identity | 1 | 2023 | 118 | 0.050 |
Why?
| | Smoking Prevention | 1 | 2003 | 164 | 0.050 |
Why?
| | Fibric Acids | 1 | 2021 | 3 | 0.050 |
Why?
| | Canada | 1 | 2003 | 353 | 0.050 |
Why?
| | Medical Oncology | 1 | 2004 | 267 | 0.050 |
Why?
| | Common Data Elements | 1 | 2021 | 12 | 0.050 |
Why?
| | Blood Platelets | 1 | 2024 | 386 | 0.050 |
Why?
| | Ceftriaxone | 1 | 2021 | 19 | 0.050 |
Why?
| | Sepsis | 1 | 2007 | 576 | 0.040 |
Why?
| | Administrative Claims, Healthcare | 1 | 2021 | 26 | 0.040 |
Why?
| | Lopinavir | 1 | 2021 | 30 | 0.040 |
Why?
| | Germany | 1 | 2021 | 100 | 0.040 |
Why?
| | Fluoroquinolones | 1 | 2021 | 45 | 0.040 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2022 | 203 | 0.040 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 55 | 0.040 |
Why?
| | Ambulatory Care Facilities | 1 | 2002 | 228 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 257 | 0.040 |
Why?
| | Ritonavir | 1 | 2021 | 73 | 0.040 |
Why?
| | China | 1 | 2021 | 192 | 0.040 |
Why?
| | Enoxaparin | 1 | 2021 | 59 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2021 | 195 | 0.040 |
Why?
| | Azithromycin | 1 | 2021 | 93 | 0.040 |
Why?
| | Age Distribution | 1 | 2021 | 371 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 125 | 0.040 |
Why?
| | Drug Combinations | 1 | 2021 | 329 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2021 | 5769 | 0.040 |
Why?
| | Medically Underserved Area | 1 | 2000 | 84 | 0.040 |
Why?
| | Needs Assessment | 1 | 2002 | 355 | 0.040 |
Why?
| | Complementary Therapies | 1 | 2000 | 89 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 10232 | 0.040 |
Why?
| | Patient Participation | 1 | 2023 | 412 | 0.040 |
Why?
| | Estradiol | 1 | 2022 | 492 | 0.040 |
Why?
| | Narration | 1 | 2020 | 56 | 0.040 |
Why?
| | Safety | 1 | 2021 | 335 | 0.040 |
Why?
| | Testosterone | 1 | 2022 | 371 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 244 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 952 | 0.040 |
Why?
| | Software Design | 1 | 2018 | 23 | 0.040 |
Why?
| | Sexual Behavior | 1 | 2023 | 481 | 0.040 |
Why?
| | Erythrocytes | 1 | 2024 | 673 | 0.040 |
Why?
| | Skin | 1 | 2003 | 724 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2734 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2019 | 109 | 0.040 |
Why?
| | Occult Blood | 1 | 2018 | 30 | 0.040 |
Why?
| | Family | 1 | 2002 | 645 | 0.040 |
Why?
| | Overweight | 1 | 2022 | 531 | 0.040 |
Why?
| | Vitamin D | 1 | 2021 | 379 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 535 | 0.030 |
Why?
| | Physicians | 1 | 2006 | 872 | 0.030 |
Why?
| | Fiber Optic Technology | 1 | 1997 | 20 | 0.030 |
Why?
| | Spiro Compounds | 1 | 1996 | 11 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1422 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 476 | 0.030 |
Why?
| | Intracranial Pressure | 1 | 1997 | 45 | 0.030 |
Why?
| | Growth Hormone | 1 | 1996 | 100 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 1983 | 0.030 |
Why?
| | Cooperative Behavior | 2 | 2011 | 432 | 0.030 |
Why?
| | Prospective Studies | 3 | 2003 | 7150 | 0.030 |
Why?
| | Colonoscopy | 1 | 2018 | 237 | 0.030 |
Why?
| | Smoking | 1 | 2003 | 1501 | 0.030 |
Why?
| | Internationality | 1 | 2016 | 150 | 0.030 |
Why?
| | United States Public Health Service | 1 | 2015 | 9 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 1997 | 261 | 0.030 |
Why?
| | Neoplasms, Radiation-Induced | 2 | 2005 | 71 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 1966 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 873 | 0.030 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1996 | 310 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2016 | 228 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2021 | 896 | 0.030 |
Why?
| | Clinical Competence | 3 | 2007 | 1015 | 0.030 |
Why?
| | Time Factors | 2 | 2021 | 6530 | 0.030 |
Why?
| | Indoles | 1 | 1996 | 387 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2018 | 738 | 0.030 |
Why?
| | Quality of Life | 2 | 2019 | 2694 | 0.030 |
Why?
| | Registries | 1 | 2021 | 1902 | 0.030 |
Why?
| | Data Collection | 2 | 2006 | 649 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2016 | 484 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2628 | 0.020 |
Why?
| | Problem-Based Learning | 1 | 2011 | 82 | 0.020 |
Why?
| | Schools, Medical | 1 | 2011 | 136 | 0.020 |
Why?
| | Health Surveys | 1 | 2011 | 493 | 0.020 |
Why?
| | MEDLINE | 1 | 2007 | 20 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1219 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1321 | 0.020 |
Why?
| | Clofibrate | 1 | 2006 | 3 | 0.020 |
Why?
| | Bezafibrate | 1 | 2006 | 10 | 0.020 |
Why?
| | Pravastatin | 1 | 2006 | 40 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 2006 | 63 | 0.020 |
Why?
| | Simvastatin | 1 | 2006 | 60 | 0.020 |
Why?
| | Bioterrorism | 1 | 2006 | 24 | 0.020 |
Why?
| | Quality Control | 1 | 2006 | 161 | 0.020 |
Why?
| | Research Personnel | 1 | 2007 | 156 | 0.020 |
Why?
| | Electronic Mail | 1 | 2006 | 60 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2008 | 261 | 0.020 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2006 | 81 | 0.020 |
Why?
| | Pyrroles | 1 | 2006 | 201 | 0.020 |
Why?
| | Animals | 1 | 2007 | 35334 | 0.010 |
Why?
| | Reproducibility of Results | 2 | 2006 | 3081 | 0.010 |
Why?
| | Hypermedia | 1 | 2004 | 1 | 0.010 |
Why?
| | Educational Measurement | 1 | 2007 | 262 | 0.010 |
Why?
| | Education, Medical, Undergraduate | 1 | 2007 | 179 | 0.010 |
Why?
| | Computers | 1 | 2004 | 64 | 0.010 |
Why?
| | Odds Ratio | 1 | 2006 | 1018 | 0.010 |
Why?
| | Beds | 1 | 2003 | 7 | 0.010 |
Why?
| | Interprofessional Relations | 1 | 2006 | 277 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2724 | 0.010 |
Why?
| | Professional Autonomy | 1 | 2002 | 29 | 0.010 |
Why?
| | Gatekeeping | 1 | 2002 | 3 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2421 | 0.010 |
Why?
| | Probability | 1 | 2002 | 302 | 0.010 |
Why?
| | Pilot Projects | 1 | 2007 | 1594 | 0.010 |
Why?
| | Research | 1 | 2004 | 419 | 0.010 |
Why?
| | Random Allocation | 1 | 2001 | 344 | 0.010 |
Why?
| | Incidence | 1 | 2006 | 2643 | 0.010 |
Why?
| | Outpatients | 1 | 2002 | 375 | 0.010 |
Why?
| | Software | 1 | 2004 | 608 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1997 | 172 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2000 | 1211 | 0.010 |
Why?
| | Administration, Oral | 1 | 1996 | 783 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2013 | 0.010 |
Why?
| | Double-Blind Method | 1 | 1996 | 1873 | 0.010 |
Why?
| | Case-Control Studies | 1 | 1997 | 3383 | 0.000 |
Why?
| | Blood Glucose | 1 | 1996 | 2071 | 0.000 |
Why?
|
|
Schilling's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|